Published in Liver Cancer on October 15, 2015
Challenges of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer (2016) 0.75
Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A (2017) 0.75
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
The future of immune checkpoint therapy. Science (2015) 5.59
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res (2009) 3.39
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (2013) 2.75
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol (2014) 1.29
Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer (2013) 1.21
How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer (2014) 1.10
A worldwide survey of the current daily practice in liver surgery. Liver Cancer (2013) 1.04
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol (2013) 1.03
Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs (2014) 0.99
Locoregional Therapy for Hepatocellular Carcinoma. Liver Cancer (2015) 0.97
Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer (2013) 0.95
Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography. Liver Cancer (2014) 0.88
Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res (2014) 0.87
Biomarkers and Personalized Sorafenib Therapy. Liver Cancer (2014) 0.85
Hyperenhanced Rim Surrounding Liver Metastatic Tumors in the Postvascular Phase of Sonazoid-Enhanced Ultrasonography: A Histological Indication of the Presence of Kupffer Cells. Oncology (2015) 0.79
Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer (2013) 0.91
Biomarkers and Personalized Sorafenib Therapy. Liver Cancer (2014) 0.85
Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma. Liver Cancer (2016) 0.81
Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma? Liver Cancer (2013) 0.81
Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B. Liver Cancer (2016) 0.77
Prediction of hepatocellular carcinoma incidence risk by ultrasound elastography. Liver Cancer (2014) 0.77
Malignant transformation of hepatocellular adenoma: how frequently does it happen? Liver Cancer (2015) 0.75
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives. Liver Cancer (2016) 0.75
Breakthrough Imaging in Hepatocellular Carcinoma. Liver Cancer (2015) 0.75
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer (2016) 0.75
Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response. Liver Cancer (2016) 0.75
Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma. Liver Cancer (2015) 0.75
Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now? Liver Cancer (2015) 0.75